Sarepta Therapeutics became the toast of biotech on Tuesday after revealing early data on a gene therapy for Duchenne muscular dystrophy that far outstripped Wall Street’s expectations.
But Sarepta is hardly alone in the field, and nothing in biotech happens in a vacuum. Here’s a look at what the latest DMD results mean for the company’s competitors.
About the Author Reprints
i want to learn more in hopes of my son being able to get in a trial
2567626615